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In vitro and in vivo evidence suggesting a role for iron in cisplatin-
induced nephrotoxicity. Cisplatin is a widely used antineoplastic agent that
has nephrotoxicity as a major side effect. The underlying mechanism of
this nephrotoxicity is still not well known. Iron has been implicated to play
an important role in several models of tissue injury, presumably through
the generation of hydroxyl radicals via the Haber-Weiss reaction or other
highly toxic free radicals. In the present study we examined the catalytic
iron content and the effect of iron chelators in an in vitro model of
cisplatin-induced cytotoxicity in LLC-PK1 cells (renal tubular epithelial
cells) and in an in vivo model of cisplatin-induced acute renal failure in
rats. Exposure of LLC-PK1 cells to cisplatin resulted in a significant
increase in bleomycin-detectable iron (iron capable of catalyzing free
radical reactions) released into the medium. Concurrent incubation of
LLC-PK1 cells with iron chelators including deferoxamine and 1,10-
phenanthroline significantly attenuated cisplatin-induced cytotoxicity as
measured by lactate dehydrogenase (LDH) release. Bleomycin-detectable
iron content was also markedly increased in the kidney of rats treated with
cisplatin. Similarly, administration of deferoxamine in rats provided
marked functional (as measured by blood urea nitrogen and creatinine)
and histological protection against cisplatin-induced acute renal failure. In
a separate study, we examined the role of hydroxyl radical in cisplatin-
induced nephrotoxicity. Incubation of LLC-PK1 cells with cisplatin caused
an increase in hydroxyl radical formation. Hydroxyl radical scavengers,
dimethyl sulfoxide, mannitol and benzoic acid, significantly reduced
cisplatin-induced cytotoxicity and, treatment with dimethyl sulfoxide or
dimethylthiourea provided significant protection against cisplatin-induced
acute renal failure. Taken together, our data strongly support a critical
role for iron in mediating tissue injury via hydroxyl radical (or a similar
oxidant) in this model of nephrotoxicity.
Cisplatin is one of the most effective chemotherapeutic agents
and plays a major role in the treatment of a variety of human solid
tumors [1]. The most common adverse effect limiting the efficacy
of the antineoplastic agent is nephrotoxicity, which develops
primarily in the S3 segment of the proximal tubule [2]. Aggressive
hydration and forced diuresis is utilized to reduce cisplatin
nephrotoxicity [3]. The mechanism underlying this nephrotoxicity
is not well understood [4].
Recent studies indicate an important role of iron in tissue injury
involving reactive oxygen species [5]. The ease with which iron is
reversibly oxidized and reduced makes iron potentially hazardous
because of its ability to participate in the generation of powerful
oxidant species, such as the hydroxyl radical via the metal
catalyzed Haber-Weiss reaction and/or in the generation of the
highly reactive iron-oxygen complexes such as ferryl or perferryl
ions [5]. In vivo most of the iron is bound to heme and non-heme
proteins, and does not directly catalyze the generation of hydroxyl
radicals or a similar oxidant [5]. Gutteridge et al have described an
assay, based on the use of the antibiotic, bleomycin, to detect iron
complexes capable of catalyzing free radical reactions in biological
samples [6]. Using this assay, an increase in iron capable of
catalyzing free radical reactions has been demonstrated in isch-
emia/reperfusion-induced acute renal failure [7], and in glycerol-
induced acute renal failure [8]. Iron chelators, including deferox-
amine and 2,3-dihydroxybenzoic acid, have been shown to be
protective in several models of acute renal failure [9–11] and
oxidant-induced cell injury [12, 13]. The role of iron in cisplatin-
induced nephrotoxicity has not been examined previously.
The major purpose of the current study was to examine the role
of catalytic iron and hydroxyl radical in an in vitro model of
cisplatin-induced cytotoxicity in LLC-PK1 cells (renal tubular
epithelial cells) and in an in vivo model of cisplatin-induced acute
renal failure in rats.
METHODS
In vitro study
Cell culture. LLC-PK1 cells (renal proximal tubular epithelial
cells), purchased from American Type Culture Collection (CRL
1392), were maintained in Medium 199 supplemented with 3%
fetal bovine serum and penicillin (100 U/ml) in a humidified
atmosphere of 95% air—5% CO2. The cells were maintained in
75 cm2 tissue culture flask and the monolayers were subcultured
using 0.05% trypsin—0.53 mM EDTA in calcium- and magne-
sium-free Hank’s balanced salt solution (HBSS). For the experi-
mental study, the cells were grown in a 6- or 12-well tissue culture
plate until confluency. All experiments were carried on confluent
cell monolayer between passages 203-215.
Cisplatin-induced cytotoxicity. On the day of the experiment, the
medium was discarded and the confluent LLC-PK1 cell monolayer
was washed twice with Hank’s balanced salt solution (HBSS). The
cells were then incubated with various concentrations of cisplatin
(0 to 500 mg/ml) for different periods of time (0 to 5 hr) in HBSS
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at 37°C. The dose of cisplatin used in the study is based on
previous studies [14, 15]. At the end of the incubation, the
incubation medium was collected and the remaining cell mono-
layer was dissolved in 0.1% Triton X-100. Lactate dehydrogenase
(LDH) in the medium and in the cellular fraction was measured
by the use of an assay kit purchased from Sigma Chemical Co. (St.
Louis, MO, USA). The degree of cell injury induced by cisplatin
was expressed as LDH release which is the percentage of LDH
released into the medium to total LDH recovered from both
medium and cellular fractions.
Effect of cisplatin on catalytic iron released. Confluent cell
monolayer was washed three times with Chelex-treated HBSS to
remove as much contaminating iron as possible. The cells were
then incubated with a cytotoxic dose of cisplatin in Chelex-treated
HBSS at 37°C for a period of time just before substantial cell
killing occurred. At the end of incubation, the incubation medium
was collected for the measurement of catalytic iron released by
bleomycin assay as described below.
Effect of cisplatin on hydroxyl radical formation. Confluent cell
monolayer was washed three times with HBSS and then incubated
with cytotoxic dose of cisplatin in HBSS at 37°C for a period of
time before substantial cell killing occurred. 2-Deoxy-D-ribose in
a final concentration of 3 mM was added to the medium just prior
to the incubation. At the end of incubation, the incubation
medium was collected for the measurement of hydroxyl radical
formation by deoxyribose degradation method described by Hal-
liwell, Grootveld and Gutteridge [16]. In brief, 0.5 ml of incuba-
tion medium was mixed with 0.5 ml of 1% (wt/vol) solution of
thiobarbituric acid in 50 mM NaOH and 0.5 ml of 2.8% (wt/vol)
aqueous trichloroacetic acid, heated at 100°C for 15 minutes,
cooled, and followed by extraction with 1.5 ml n-butanol. The
resulting supernatant was then read at 532 nm and the amount of
hydroxyl radical formation was calculated by using the extinction
coefficient of 156 mM21 cm21.
Effect of iron chelators and hydroxyl radical scavengers on
cisplatin-induced cytotoxicity. Confluent cell monolayer was
washed out of medium and then incubated with a cytotoxic dose
of cisplatin in HBSS at 37°C for a period of time necessary to
induce consistent cytotoxicity. Iron chelators, deferoxamine and
1,10-phenanthroline, and hydroxyl radical scavengers, dimethyl
sulfoxide, mannitol and benzoic acid, were used to increase the
reproducibility. Deferoxamine (DFO; 1 mM), 1,10-phenanthroline
(0.1 mM), dimethyl sulfoxide (DMSO; 5 mM), mannitol (50 mM) or
benzoic acid (100 mM) was added to the incubation medium just
prior to the addition of cisplatin. Lactate dehydrogenase (LDH)
release was measured at the end of the incubation.
Effect of iron chelator on platinum level. To exclude the possi-
bility that an iron chelator may interfere with the platinum level of
cisplatin, cisplatin at a dose to induce consistent cytotoxicity (200
mg/ml) was incubated with or without the iron chelator, deferox-
amine, in a range of 1 to 5 mM and then the platinum level was
measured by atomic absorption spectroscopy with electrothermal
atomization. The assay was performed by Dr. Thomas Moyer in
the Department of Laboratory Medicine and Pathology at Mayo
Clinic in Rochester, Minnesota.
In vivo study
Cisplatin-induced acute renal failure. The cisplatin model of
acute renal failure was induced in rats as described by Capasso et
al [17]. Male Sprague-Dawley rats weighing 200 to 250 g were
allowed free access to rat chow (Purina) and water. The animals
received intraperitoneal injection of cisplatin (Bristol-Myers
Squibb Co., Princeton, NJ, USA) at a dose of 10 mg/kg body wt
and were sacrificed 72 hours after cisplatin injection. Blood and
kidneys were obtained for the various measurements. Renal
impairment was assessed by blood urea nitrogen and plasma
creatinine as well as kidney histology. Blood urea nitrogen (BUN)
and creatinine were measured by the use of Sigma diagnostic kits.
Kidney histology was studied as described in the following section.
Effect of iron chelator and hydroxyl radical scavengers on cisplatin
model of acute renal failure. The iron chelator, DFO and hydroxyl
radical scavengers, DMSO or dimethylthiourea (DMTU), were
used in separate experiments with rats receiving cisplatin treat-
ment. DFO was administered via an osmotic pump (type 2 ML-1;
ALZA Corp. Palo Alto, CA) that was implanted subcutaneously
24 hours prior to cisplatin injection until sacrifice. The drug was
reconstituted in water at a concentration of 125 mg/ml, and the
pumps (with a 2 ml capacity) delivered approximately 30 mg DFO
per rat per day at a continuous rate of 10 ml/hr [9, 11]. DMSO was
administered via intraperitoneal injection twice a day at a dose of
4 g/kg body wt until sacrifice [9]. The first dose of DMSO was
given four hours prior to cisplatin injection. DMTU and urea
(which is not a hydroxyl radical scavenger and serves as a control)
were administered via intraperitoneal injection 30 minutes prior
to cisplatin injection at a dose of 500 mg/kg body wt, followed by
twice a day at a dose of 125 mg/kg body wt until sacrifice [9].
Kidney histology. The kidneys were sectioned and a portion fixed
in 10% formalin, dehydrated and embedded in paraffin. Sections
were cut at 2 mm and stained with periodic acid-Schiff reagent.
The slides were coded and semiquantitative analysis of the kidney
sections was performed without knowledge of the treatment
protocol. The changes seen were limited to the tubulointerstitial
areas and graded as follows: 0, normal; I, areas of tubular
epithelial cell swelling, vacuolar degeneration, necrosis, and des-
quamation involving ,25% of cortical tubules; II, similar changes
involving .25% but ,50% of cortical tubules; III, similar changes
involving .50% but ,75% of cortical tubules; IV, similar changes
involving .75% of cortical tubules [18].
Bleomycin-detectable iron assay. Catalytic iron (capable of cat-
alyzing free radical reactions) released into the culture medium or
present in kidney was measured by the bleomycin assay developed
as detailed in our previous study [7]. For the measurement of iron
in the kidney, tissues were homogenized in Chelex-treated pyro-
gen-free water, loaded into a Centriprep-30 which has a cut-off
value of 30,000 kDa, and centrifuged at 4°C for 30 minutes at
1500 g. The clear ultrafiltrate was collected and used for bleomy-
cin-detectable iron determination.
One milliliter of the reaction mixture contained in order: 0.5 ml
of calf thymus DNA (1 mg/ml), 0.05 or 0.1 ml of bleomycin sulfate
(1 mg/ml), 0.1 ml of MgCl2 (50 mM), 0.1 ml of sample, 0.1 ml of
Chelex-treated pyrogen-free water, 0.1 ml of ascorbic acid (8 mM),
and either 0.05 ml of HCl (10 mM) [7] or 0.1 ml of imidazole (1.0
M, pH 7.3) [19] to adjust to pH 7.4. Sample blanks were identical
except that bleomycin was omitted. The samples were then
incubated at 37°C for two hours with shaking. The reaction was
stopped by adding 0.1 M EDTA, and mixed with 1 ml of
thiobarbituric acid (1% wt/vol in 50 mM NaOH) and 1 ml of 25%
HCl (vol/vol). The reaction mixture was then heated at 100°C for
15 minutes, cooled, and the resulting chromogen measured using
spectrophotometer by its absorbance at 532 nm. A standard curve
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was prepared using known amounts of FeCl3 in Chelex-treated
pyrogen-free water. The amount of bleomycin-detectable iron in
the test sample was calculated from the standard curve and the
results expressed as either nmol/mg cellular protein recovered
from the cell monolayer or nmol/mg tissue protein recovered from
the homogenate. Protein was measured by the use of Bio-Rad
reagent. All reagents except for the sample under test, were made
up in Chelex-treated pyrogen-free water and shaken with Chelex-
100 to remove as much contaminating iron as possible.
Statistical analysis
Values are expressed as mean 6 standard error (SE). Statistical
analyses were performed using unpaired t-test (for only two
groups) and analysis of variance (for more than two groups).
Statistical significance was considered at P , 0.05.
RESULTS
We first examined the time course and dose-dependent effect of
cisplatin on irreversible cell death in LLC-PK1 cells as measured
by LDH release. As shown in Figure 1A, cisplatin-induced cell
death to LLC-PK1 cells was first observed with a dose of 50 mg/ml
with increasing cytotoxicity with the highest dosage tested of 500
mg/ml. Based on the concentration-dependent effect of cisplatin
at four hours, we chose the concentration, 200 mg/ml of cisplatin,
which was the dose required to cause submaximal injury over a
two hour period. Exposure of LLC-PK1 cells to cisplatin at a
cytotoxic dose (200 mg/ml) resulted in significant increase in LDH
release at three hours with increases up to five hours (Fig. 1B).
LLC-PK1 cells incubated for 2.5 hours without cisplatin had
1.06 6 0.27 nmol/mg protein catalytic iron (as measured by
bleomycin-detectable iron assay) in the medium. Exposure of
LLC-PK1 cells to cisplatin resulted in a marked increase (5.86 6
0.46 nmol/mg protein, N 5 4, P , 0.01) in catalytic iron released
into the medium (Fig. 2). We have previously shown that catalytic
iron does not increase nonspecifically as a result of cell injury or
in homogenized tissue [7]. In separate experiments we examined
the effect of metal chelators, DFO and 1,10-phenanthroline, on
cisplatin-induced cytotoxicity in LLC-PK1 cells (Fig. 3). LLC-PK1
cells incubated with 200 mg/ml of cisplatin for four hours resulted
in 78 6 2% LDH release compared to control value of 5 6 1%
(N 5 4, P , 0.01). Both DFO and 1,10-phenanthroline completely
prevented the cytotoxicity with LDH release being reduced to
3.3 6 0.7% and 3.0 6 0.3%, respectively. These concentrations of
DFO and 1,10-phenanthroline also prevented increases in the
bleomycin-detectable iron (data not shown).
In an in vivo study we examined the catalytic iron in the kidney
in a model of cisplatin-induced acute renal failure. Cisplatin at a
dose of 10 mg/kg intraperitoneally resulted in acute renal failure
(Fig. 4 A, B). The bleomycin-detectable iron content in the kidney
was significantly increased from a control value of 0.85 6 0.06 to
1.7 6 0.09 nmol/mg protein (N 5 5, P , 0.01) in rats treated with
cisplatin (Fig. 4C). We examined the effect of DFO on cisplatin-
induced acute renal failure. Rats treated with cisplatin and
concurrently treated with DFO had significantly less deterioration
in renal function (BUN, 66 6 13 mg/dl; creatinine, 1.50 6 0.28
mg/dl; N 5 10, P , 0.01) compared to rats receiving cisplatin
alone (BUN, 109 6 6 mg/dl; creatinine, 2.58 6 0.19 mg/dl; N 5 10,
P , 0.01; Fig. 5). In a separate study utilizing a cell-free system,
we confirmed that the level of cisplatin measured with and without
an iron chelator, DFO was similar, indicating that the protective
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Fig. 1. Concentration-dependent and time-dependent effect of cisplatin
on cytotoxicity in LLC-PK1 cells. Confluent cell monolayer was incubated
with various concentrations of cisplatin for different periods of time as
indicated. Lactate dehydrogenase (LDH) release was measured at the end
of incubation. (A) Concentration-dependent effect of cisplatin (0 to 500
mg/ml, 4 hr) on cytotoxicity as measured by LDH release in LLC-PK1 cells.
(B) Time course of cisplatin (200 mg/ml, 0 to 5 hr) on cytotoxicity as
measured by LDH release in LLC-PK1 cells. Values are means 6 SE, N 5
2.
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effect of DFO was unlikely to be due to chelation of cisplatin
(data not shown).
Iron has been shown to participate in the generation of
powerful oxidant species, such as the hydroxyl radical via the
metal catalyzed Haber-Weiss reaction [5]. We thus examined the
potential role of hydroxyl radical in cisplatin-induced cytotoxicity
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Fig. 2. Effect of cisplatin on catalytic iron released as measured by
bleomycin-detectable iron in LLC-PK1 cells. Confluent cell monolayer
was washed with Chelex-treated Hank’s balanced salt solution (HBSS) to
remove contaminating iron and then incubated with 200 mg/ml of cisplatin
for 2.5 hours in Chelex-treated HBSS. At the end of the incubation, the
incubation buffer was collected for the measurement of bleomycin-
detectable iron as described in the Methods section. Values are means 6
SE, N 5 4, *P , 0.01, compared with control cells.
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Fig. 3. Effect of iron chelators on cisplatin-induced cytotoxicity as mea-
sured by lactate dehydrogenase (LDH) release in LLC-PK1 cells. Conflu-
ent cell monolayer was incubated with 200 mg/ml of cisplatin for four
hours. Iron chelators including deferoxamine (DFO, 1 mM) and 1,10-
phenanthroline (1,10 PA, 0.1 mM) were added to the medium just prior to
the addition of cisplatin. LDH release was measured at the end of
incubation as described in the Methods section. Values are means 6 SE.
N 5 4, *P , 0.01, compared with cisplatin treatment alone.
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Fig. 4. Cisplatin-induced acute renal failure as measured by (A) blood
urea nitrogen, (B) plasma creatinine and (C) bleomycin-detectable iron
content in the kidney. Cisplatin model of acute renal failure in rats was
induced by intraperitoneal injection of cisplatin at a dose of 10 mg/kg body
wt. The animals were sacrificed 72 hours after cisplatin injection. Bleo-
mycin-detectable iron was measured as described in the Methods section.
Values are means 6 SE, N 5 5, *P , 0.01 compared with control animals.
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both in in vitro and in vivo studies. As shown in Figure 6, there was
a significant increase in the formation of hydroxyl radicals while
exposing the LLC-PK1 cells to cisplatin at a cytotoxic dose (200
mg/ml). We examined the effect of hydroxyl radical scavengers on
cisplatin-induced cytotoxicity to LLC-PK1 cells utilizing the doses
similar to those that we have previously shown to scavenge
hydroxyl radical in a cell-free system [20]. Compared to cells
treated with cisplatin alone (LDH release, 76 6 4%), hydroxyl
radical scavengers, DMSO (31 6 2%), mannitol (36 6 2%), and
benzoic acid (41 6 3%, N 5 4, P , 0.01) provided a marked
protection against cisplatin-induced cytotoxicity in LLC-PK1 cells
(Fig. 7). In an in vivo study, rats treated concurrently with DMSO
had significant protection (BUN, 49 6 10 mg/dl; creatinine,
1.19 6 0.20 mg/dl, N 5 7, P , 0.01) compared to rats treated with
cisplatin alone (BUN, 95 6 10 mg/dl; creatinine, 2.00 6 0.18
mg/dl, N 5 7; Fig. 8 A, B). In a separate study, we examined the
effect of another hydroxyl radical scavenger, DMTU and urea
(which is not a hydroxyl radical scavenger but serves as a control)
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Fig. 5. Effect of iron chelator deferoxamine (DFO) on cisplatin-induced
acute renal failure as measured by (A) blood urea nitrogen and (B)
plasma creatinine. The cisplatin model of acute renal failure in rats was
induced by intraperitoneal injection of cisplatin at a dose of 10 mg/kg body
wt. DFO was administered via an osmotic pump which was implanted
subcutaneously and delivered approximately 30 mg DFO per rat per day
until sacrifice. The animals were sacrificed 72 hours after cisplatin
injection. Values are means 6 SE. The number of animals used is
indicated. *P , 0.01, compared with cisplatin treatment alone.
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Fig. 6. Effect of cisplatin on hydroxyl radical formation in LLC-PK1
cells. Confluent cell monolayer was incubated with 200 mg/ml of cisplatin
for 2.5 hours in HBSS. 2-Deoxy-D-ribose was added to the medium just
prior to the incubation. At the end of the incubation, the incubation
medium was collected for the measurement of hydroxyl radical formation
as described in the Methods section. Values are means 6 SE, N 5 3, *P ,
0.01, compared with control cells.
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Fig. 7. Effect of hydroxyl radical scavengers on cisplatin-induced cyto-
toxicity as measured by lactate dehydrogenase (LDH) release in LLC-PK1
cells. Confluent cell monolayer was incubated with 200 mg/ml of cisplatin
for four hours. Hydroxyl radical scavengers including dimethyl sulfoxide
(DMSO, 5 mM), mannitol (50 mM) and benzoic acid (100 mM) were added
to the medium just prior to the addition of cisplatin. LDH release was
measured at the end of incubation as described in the Methods section.
Values are means 6 SE. N 5 4, *P , 0.01, compared with cisplatin
treatment alone.
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on cisplatin nephrotoxicity. As shown in Figure 8 C and D, rats
pretreated with DMTU had significant protection (BUN, 33 6 11
mg/dl; creatinine, 0.47 6 0.03 mg/dl, N 5 6, P , 0.01) compared
to rats treated with cisplatin alone (BUN, 98 6 12 mg/dl;
creatinine, 1.23 6 0.15 mg/dl, N 5 3). However, the pretreatment
of rats with urea had no effect on cisplatin nephrotoxicity (BUN,
106 6 4 mg/dl; creatinine, 1.30 6 0.20 mg/dl, N 5 5). The lack of
effect of urea indicates that the protective effect of DMSO or
DMTU is most likely due to their ability to be oxidant scavengers
rather than due to osmotic diuresis.
We also examined the histological changes in the kidney
obtained from 5 rats in each of the groups (control, cisplatin
alone, cisplatin 1 DFO, cisplatin 1 DMSO). Renal function
studies in these subsets were not different from the overall
experimental groups (control: BUN, 26 6 2 mg/dl, creatinine,
0.69 6 0.05 mg/dl; cisplatin alone: BUN, 121 6 3 mg/dl, creati-
nine, 2.67 6 0.25 mg/dl; cisplatin 1 DFO: BUN, 58 6 20 mg/dl,
creatinine, 1.37 6 0.44 mg/dl; cisplatin 1 DMSO: BUN, 51 6 11
mg/dl, creatinine, 1.20 6 0.6 mg/dl). The histological changes
were graded as described in the methods and the results expressed
in Table 1. Compared to control rats (Fig. 9A), in rats treated with
cisplatin there was extensive epithelial cell vacuolization, swelling,
desquamation and necrosis (grade IV) occurring predominantly
in the proximal convoluted tubules (Fig. 9B). Rats treated with
the iron chelator, DFO (Fig. 9C), or the hydroxyl scavenger,
DMSO (Fig. 9D), had a marked reduction in the extent of tubular
damage (grade I-II).
DISCUSSION
In the present study, we demonstrate that catalytic iron, as
measured by bleomycin assay, was significantly increased in
LLC-PK1 cells exposed to cisplatin and in the kidney of rats
treated with cisplatin. Iron chelators including DFO and 1,10-
phenanthroline completely prevented cisplatin-induced cytotoxic-
ity in LLC-PK1 cells and DFO also provided marked protection
against cisplatin-induced acute renal failure in rats. Taken to-
gether, these data suggest that the catalytic iron plays an impor-
tant role in the pathogenesis of this model of renal injury.
An iron chelator, DFO, has been shown to substantially reduce
the myocardial, hematological and hepatotoxicity induced by
various chemotherapeutic agents [21, 22]. In previous studies [23],
DFO has been shown to be effective in reducing the gastro-
intestinal side effects following the administration of cisplatin. In
an in vivo study [24], pretreating with DFO in a single dose at 30
minutes prior to cisplatin administration was not protective
against cisplatin nephrotoxicity despite a marked decrease in lipid
peroxidation. The lack of protective effect may be related to the
half-life of DFO when compared to the prolonged half-life of
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Fig. 8. Effect of hydroxyl radical scavengers
dimethyl sulfoxide (DMSO) or
dimethylthiourea (DMTU) on cisplatin-induced
acute renal failure as measured by blood urea
nitrogen (A and C) and plasma creatinine (B
and D). Cisplatin model of acute renal failure
in rats was induced by intraperitoneal injection
of cisplatin at a dose of 10 mg/kg body wt.
DMSO was administered via intraperitoneal
injection twice a day at a dose of 4 g/kg body
wt 4 hours prior to cisplatin injection until
sacrifice. DMTU or urea (which is not a
hydroxyl radical scavenger and serves as a
control) was administered via intraperitoneal
injection 30 minutes prior to cisplatin injection
at a dose of 500 mg/kg body wt, followed by
twice a day at a dose of 125 mg/kg body wt
until sacrifice 72 hours after cisplatin injection.
Values are means 6 SE. The number of animals
used is indicated. *P , 0.01, compared with
cisplatin treatment alone.
Table 1. Semiquantitative analysis of renal tubule histology in rats
Group N
Histologic grade
0-trace I II III IV
Control 5 5
Cisplatin 5 3 2
1 Deferoxamine 5 1 2 1 1
1 Dimethyl sulfoxide 5 2 2 1
Five rats in each group were obtained for kidney histology study. Renal
function study in these subsets was not different from the overall
experimental groups. Renal tubule histologic grading is as follows: 0,
normal; I, areas of tubular epithelial cell swelling, vacuolar degeneration,
necrosis, and desquamation involving , 25% of cortical tubules; II, similar
changes involving . 25% but , 50%; III, similar changes involving . 50%
but , 75% of cortical tubules; IV, similar changes involving . 75%.
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cisplatin in a seven-day model of renal injury, where there is
substantial accumulation in the tissue that exceeds concentration
in the plasma and other organs.
One of the important mechanisms by which iron mediates tissue
injury is the generation of the highly toxic hydroxyl radical via the
iron catalyzed Haber-Weiss reaction [5]. An increased hydroxyl
radical formation has been demonstrated in renal tubular cells
subjected to hypoxia/reoxygenation [12, 25]. Hydroxyl radical
scavengers have also provided marked protection against ischemic
[26], aminoglycoside-induced [9], as well as myoglobinuric acute
renal failure [11]. The protective effects of iron chelators and
hydroxyl radical scavengers in several models of renal injury have
been generally taken as evidence for the participation of hydroxyl
radical in tissue damage because iron is critical in the generation
of hydroxyl radical via the Haber-Weiss reaction [9–11, 26].
Particularly relevant to the current study is the observation in
which cisplatin has been shown to generate hydroxyl radical by
interaction with DNA in a cell free system [27]. The present study
demonstrated that exposure of LLC-PK1 cells to cisplatin resulted
in significant increase in hydroxyl radical formation. Hydroxyl
radical scavengers, DMSO, mannitol and benzoic acid signifi-
cantly reduced cisplatin-induced cytotoxicity and, treatment with
DMSO or DMTU provided significant protection against cispla-
tin-induced acute renal failure.
We did not examine the mechanisms by which oxidants cause
cisplatin cytotoxicity and acute renal failure. However, we and
others have demonstrated an important role of iron in oxidant
injury to renal tubular epithelial cells [13, 28], and demonstrated
DNA fragmentation and endonuclease activation, both consid-
ered biochemical features of apoptosis, in oxidant-mediated injury
to LLC-PK1 cells [29]. In a recent study it was shown that cisplatin
induces proximal tubular epithelial cell injury both by apoptosis
with DNA fragmentation and chromatin condensation as well as
necrosis in higher doses [30]. Thus, it is conceivable that cisplatin-
induced cytotoxicity may be the result of oxidant-induced DNA
damage. Based on cisplatin’s ability to induce lipid peroxidation
both in vitro and in vivo, lipid peroxidation is another iron-related
mechanism that may be important in cisplatin cytotoxicity [31, 32].
In addition, treatment with antioxidants including a-tocopherol,
N-N9-diphenyl-p-phenylendiamine and ascorbic acid, significantly
attenuated cisplatin-induced acute renal failure in rats [33], or
cytotoxicity in cultured renal epithelial cells [34].
Fig. 9. Light-microscopy section of kidney. (A) Control rat showing no abnormalities. (B) Rat treated with cisplatin showing extensive epithelial cell
vacuolization, swelling, desquamation and necrosis (grade IV) occurring predominantly in the proximal convoluted tubules. (C) Rat treated with the
iron chelator, deferoxamine (DFO), and (D) the hydroxyl radical scavenger, dimethyl sulfoxide (DMSO), both of which show a marked reduction in
the extent of tubular damage (grade I-II).
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In summary, our study clearly demonstrates that bleomycin-
detectable iron is significantly increased in in vitro and in vivo
models of cisplatin-induced nephrotoxicity. Treatment with both
iron chelators and hydroxyl radical scavengers substantially pre-
vented cytotoxicity and acute renal failure induced by cisplatin.
Taken together, our data lend strong support to a critical role for
iron in mediating tissue injury via hydroxyl radical formation in
cisplatin-induced nephrotoxicity. However, additional studies
would be necessary to determine whether iron chelators can
prevent nephrotoxicity in humans as well as whether iron chela-
tion therapy affects the tumorocidal effect of cisplatin.
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APPENDIX
Abbreviations used in this article are: BUN, blood urea nitrogen; DFO,
deferoxamine; DMSO, dimethyl sulfoxide; DMTU, dimethylthiourea;
HBSS, Hank’s balanced salt solution; LDH, lactate dehydrogenase.
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